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The relationship between the antigen dose and the quality of an immune response generated upon
immunization is poorly understood. However, findings show that the immune system is indeed influ-
enced by the antigen dose; hence underlining the importance of correctly determining which dose to
use in order to generate a certain type of immune response.
To investigate this area further, we used Göttingen minipigs as an animal model especially due to the
similar body size and high degree of immunome similarity between humans and pigs. In this study, we
show that both a humoral and a cell-mediated immune (CMI) response can be generated following
intraperitoneal immunization with tetanus toxoid (TT) formulated in the CAF09 liposomal adjuvant.
Importantly, a low antigen dose induced more TT-specific polyfunctional T cells, whereas antigen-
specific IgG production was observed upon high-dose immunization. Independent of antigen dose,
intraperitoneal administration of antigen increased the amount of TT-specific cytotoxic CD8b+ T cells
within the cytokine-producing T-cell pool when compared to the non-cytokine producing T-cell compart-
ment.
Taken together, these results demonstrate that a full protein formulated in the CAF09 adjuvant and
administered to pigs via the intraperitoneal route effectively generates a cytotoxic T-cell response.
Moreover, we confirm the inverse relationship between the antigen dose and the induction of polyfunc-
tional T cells in a large animal model. These finding can have implications for the design of upcoming vac-
cine trials aiming at establishing a cytotoxic T-cell response.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Vaccines can contain different amounts of target antigen; how-
ever, it is not well known how the antigen dose influences the
quality of a resulting immune response. Relatively few studies
directly investigate this, although an inverse relationship between
antigen dose and the duration of delayed type hypersensitivity has
been proposed [1]. Also, it has been hypothesized that more T cellsand antigen are required for Th2 than Th1 responses [2]. Recent
findings further support an inverse relationship between the anti-
gen dose and the induction of CD4+ T-cell polyfunctionality and
functional avidity in both mice and humans [3–5].
Given that the antigen dose can influence the immune response,
correctly determining the first-in-human dose based on preclinical
animal studies becomes even more crucial, and translating findings
from preclinical vaccine research is dependent on animal models
reliably mimicking human patients. Previously, the body weight
of the animal alone has been used for extrapolation; but due to
resulting unsuccessful clinical trials, using the body surface area
(BSA) of the animal has been a suggested approach [6]. However,
the BSA method still shows extreme inaccuracy [7]; suggesting
the need for further improvement in strategies converting animal
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antigen dose on the immune response.
In contrast to rodents; the porcine metabolic rate, important
metabolic enzymes, and the immunome closely resemble the
human counterparts [8–11]. Moreover, pigs are fully immune com-
petent and display high MHC-allelic diversity with the number of
known porcine MHC class I alleles continuously expanding due
to an improved detection method [12]. For vaccine research to be
reliably translated to humans, it is crucial to perform the preclini-
cal tests in an animal model with a fully competent immune sys-
tem [13,14]; further supporting the potential in using pigs as a
large animal model in the interphase from early rodent work to
clinical trials in humans.
In this study, we hypothesised that a cytotoxic immune
response can be generated in pigs following intraperitoneal (i.p.)
immunization. Moreover, we hypothesized that the quality of the
resulting immune response is influenced by the antigen dose. Teta-
nus toxoid (TT) was used as a model antigen and formulated in
CAF09; a dimethyldioctadecylammonium bromide liposomal adju-
vant with synthetic monomycolyl glycerol and the TLR3 agonist
poly I:C as immune modulators [15]. We i.p. administered 10-
fold titrations of the full TT protein to Göttingen minipigs and
investigated effects of antigen dose on the humoral and cell-
mediated immune (CMI) response to further evaluate the potential
of pigs for translational vaccine research.2. Materials and methods
2.1. Pigs
Fifteen Göttingen minipigs aged 2 to 4.5 months and derived
from four different litters were purchased from Ellegaard A/S (Sorø,
Denmark), housed at the National Veterinary Institute, Technical
University of Denmark (Frederiksberg C, Denmark) and random-
ized into three groups based on sex, litter, and weight (n = 5). Ani-
mal procedures were carried out in accordance with both national
and international guidelines, and all procedures comply with the
ARRIVE guidelines. The institutional committee as well as the Dan-
ish Animal Experiments’ Inspectorate (Ethical approval ID: 2012
15293400557) approved all procedures.2.2. Immunizations
Animals received either 1 µg, 10 µg, or 100 µg of purified TT
(State Serum Institute, batch: T 262-01) formulated in the CAF09
adjuvant as previously described [15]. The CAF09 adjuvant was
kindly provided by Dennis Christensen (Statens Serum Institut,
Copenhagen, Denmark). Each immunization was comprised of
1 ml CAF09 and 1 ml TT diluted in 10 mM Tris buffer. Immuniza-
tions were delivered via the intraperitoneal (i.p.) route using an
18G  200 needle; no anaesthesia was used. Animals were primed
and subsequently boosted twice with two week intervals (Supp.
Table 1).2.3. Cell isolation
Blood was collected into sodium heparinized vacutainer tubes
(BD Diagnostics, catalogue number (cat.): 362753) and purified
using SepMate tubes (StemCell Technologies, cat.: 85450) accord-
ing to manufacturer’s protocol. In brief, the blood was diluted in
PBS/2%FBS (ThermoFischer Scientific, cat.: 10082147) and sepa-
rated using Lymphoprep (StemCell Technologies, cat.: 07851). Fol-
lowing separation, the cells were counted using the Nucleocounter
NC-200 (Chemometec, Allerød, Denmark).2.4. IFN-c ELISpot
MultiScreenHTS IP Filter Plates (Merck Millipore, cat.:
MSIPS4510) were pre-wet in 35% ethanol (v/v in sterile milliQ
water) and coated with 5 µg/ml mouse anti-swine IFN-c antibody
(ThermoFischer Scientific, cat.: MP700) overnight at 4 C. The
plates were blocked with AIM VTM media (ThermoFischer Scientific,
cat.: 12055091), no serum, for at least one hour at 37 C. To each
well, 2  105 freshly isolated PBMCs were added and incubated
for 20 h at 37 C in the presence of 1.5 µg/ml TT, 1.5 µg/ml staphy-
lococcal enterotoxin B (SEB) (Sigma Aldrich, cat.: S4881) as positive
control, or media alone. Biotin Mouse Anti-Pig IFN-c (BD Bio-
sciences, cat.: 559958) was used at 1 µg/ml for detection with incu-
bation for 1 h at room temperature (RT). Streptavidine-Alkaline
Phophatase conjugate (Sigma Aldrich, cat.: 11 089 161 001) was
diluted 1:2000 and added to the plates with incubation on a shak-
ing table for 1 h at RT. Finally, 100 µl/well of BCIP/NBT Liquid Sub-
strate System (Sigma Aldrich, cat.: B1911) was added and spot
development was terminated after five minutes. The plates were
allowed to air-dry in the dark. The AID EliSpot Reader version 6.0
(Autoimmun Diagnostika GmbH, Strassberg, Germany) was used
for analysis. Data is shown with subtraction of the background
levels of spot forming cells (SFCs) from culturing with media alone.
2.5. IgG ELISA
The 96-well polysorp plate (ThermoFischer Scientific, cat.:
475094) was coated with 0.125 µg/ml TT and incubated overnight
at 4 C. Serum samples, diluted 1:10,000, were added to the plate
with incubation on a shaking table for 1 h at RT. Biotinylated goat
anti-pig IgG (Bio-Rad, cat.: AAI41), was diluted 1:20,000 and used
as secondary antibody with incubation on a shaking table for 1 h at
RT. HRP-conjugated streptavidin (ThermoFischer Scientific, cat.:
N100) diluted 1:8000 was added; the plate was incubated on a
shaking table for 1 h at RT. Finally, tetramethylbenzidine (Kem-
En-Tec, cat.: 4380 L) was added and the reaction was terminated
with 0.5 M sulfuric acid after five min at RT. A microplate reader
(ThermoFischer Scientific) was used to determine the absorbance
at 450 nm; corrections for unspecific background were done by
subtraction of the signal at 650 nm.
2.6. Flow cytometry
Antibodies were used at pre-determined concentrations (details
in Supp. Table 2). PBMCs were stimulated for 16 h with 2 µg/ml TT,
media alone, or 1 µg/ml SEB as a positive control, followed by 6 h
culturing in the presence of 10 µg/ml Brefeldin A (Sigma-Aldrich,
cat.: B7651-5MG). Cells were surface stained for 30 min at 4 C
with antibodies against CD3 and CD8b in combination with a
live/dead stain. Fixation/Permeabilization Solution Kit (BD
Biosciences, cat.: 554714) was used according to manufacturer’s
protocol. Intracellular cytokine staining was conducted using
antibodies against IFN-c, TNF-a, and perforin for 30 min at 4 C.
Samples were acquired on an LSRFortessa (BD Bioscience) flow
cytometer, and 200,000 viable CD3+ cells were recorded for
analysis. Data was analysed using FlowJo Data Analysis Software
version 10.
2.7. Statistical analysis
Despite low numbers of animals, the data were analysed by
parametric analyses as non-baseline data passed the Shapiro-
Wilk normality test and presumably represent normally dis-
tributed populations. Results are thus shown as the mean or the
mean ± SEM and statistical comparisons were performed using
either paired or unpaired Student’s t-test. GraphPad Prism version
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cal analysis. P < 0.05 (⁄) was considered significant, and P < 0.005
(⁄⁄), P < 0.001 (⁄⁄⁄), and P < 0.0001 (⁄⁄⁄⁄) are indicated.3. Results
3.1. Immunization with a low antigen dose drives a CMI response
We firstly evaluated the amount of IFN-c produced during the
immunization trial. Prior to immunization, all animals were TT
naïve as demonstrated by the lack of IFN-c SFCs at day 0
(Fig. 1A). A quantification of the IFN-c SFCs in response to
CAF09-formulated TT revealed that a CMI response was generated
in all the groups already at day 27 (Fig. 1B). The immune response
in each group was enhanced by an additional immunization as
indicated by the presence of more IFN-c SFCs at day 41; most pro-
nounced in the 1 µg and 10 µg group (Fig. 1B). Additionally, we
investigated whether several rounds of i.p. immunization induced
a humoral immune response. No TT-specific IgG antibodies were
detected in serum samples prior to the first immunization in any
of the groups (Fig. 1C). Two immunizations were sufficient to gen-
erate TT-specific IgG antibodies only in the 100 µg dose group;
however, all groups displayed a humoral response to TT following
three injections (Fig. 1C). A comparison of the three immunization
groups revealed that animals receiving 1 µg TT produced a stronger
TT-specific IFN-c response when compared to animals receiving
100 µg TT (Fig. 1D). In contrast, immunization with a high antigen
dose induced a stronger humoral immune response (Fig. 1E).
3.2. T-cell-derived IFN-c is enhanced by immunization with a low
antigen dose
Having established that the dose of immunizing antigen
affected the subsequent IFN-c responses detected by ex vivo IFN-
c ELISpot, we further investigated the effect of antigen dose
directly on T cells. The capacity of T cells to produce IFN-c against
TT following in vitro re-stimulation at day 41 was determined by
flow cytometry; a representative gating strategy is depicted in
Supp. Fig. 1.
Although numbers of IFN-c+ TT-specific T cells were small, the
flow cytometric plots clearly indicated that T cells derived from
the 1 µg, and somewhat also the 10 µg group, were IFN-c+ while
animals receiving 100 µg of CAF09-formulated TT did not seem
to respond (Fig. 2A). This was substantiated by a statistically signif-
icant higher percentage of T cells producing IFN-c against TT in
animals receiving 1 µg of antigen compared to 100 µg immunized
pigs (Fig. 2B). Interestingly, a titration effect could be observed
across the groups (Fig. 2B); thus suggesting an inverse relationship
between the percentage of IFN-c+ T cells and the CAF09-
formulated antigen dose. Analysis of the CD3 population did not
reveal IFN-c producing cells in response to TT (data not shown).
3.3. TT-specific cytotoxic CD8b+ T cells are increased within the IFN-c+
T-cell population
Given that the antigen dose when formulated in CAF09 is inver-
sely correlated with the amount of IFN-c responsive T cells, we fur-
ther investigated whether the phenotype of the T cells was also
affected by the antigen dose. The CD8b marker was used to distin-
guish between cytotoxic and helper T cells as previously described
[16]. The ratio between CD8b+ and CD8b T cells was evaluated in
both the IFN-c and the IFN-c+ T-cell population for all groups
(Fig. 3A–C). When quantifying the ratios, a significant increase in
CD8b+ T cells was detected in the IFN-c+ T-cell population for both
the 1 µg (Fig. 3D) and the 10 µg group (Fig. 3E). In the high dosegroup, four out of five animals also showed a tendency towards
an increase in CD8b+ T cells within the IFN-c+ T-cell population
(Fig. 3F). Taken together, these results demonstrate that the TT-
specific CTLs are increased within the IFN-c+ T-cell population
independently of the antigen dose formulated in CAF09.
3.4. TNF-a+ T cells are slightly increased when immunizing with a low
antigen dose
In addition to IFN-c, TNF-a is an important effector molecule
produced by cytotoxic CD8+ T cells [17]. For this reason, we inves-
tigated whether TNF-a was also affected by the antigen dose. The
ability of T cells to produce TNF-a in response to TT was again eval-
uated using flow cytometry; a representative gating strategy is
outlined in Supp. Fig. 1. Across all groups and in all individual ani-
mals, TNF-a-producing T cells were readily detectable (Fig. 4A).
When comparing the percentage of TNF-a+ T cells, no difference
could be observed between the 1 µg and the 10 µg groups, while
four out of five pigs in the 100 µg group were non-responders
(Fig. 4B). Although non-significant, a trend towards an inverse rela-
tionship between CAF09-formulated antigen dose and the ability of
T cells to produce TNF-a could thus be observed (Fig. 4B).
3.5. TT-specific cytotoxic CD8b+ T cells are increased within the TNF-a+
T-cell population
Since the cytokine-producing T-cell population was shifted
towards a cytotoxic phenotype when measuring IFN-c (Fig. 3),
we speculated whether this would also be the case for TNF-a.
The relationship between cytotoxic and helper T cells, as deter-
mined by the expression of the CD8b molecule, was determined
within the TNF-a-producing and TNF-a T-cell population
(Fig. 5A–C). An increase in the amount of CD8b+ T cells in the
TNF-a+ population was observed for all groups, when comparing
to the TNF-a population (Fig. 5A–C). This observation was clearly
supported by a statistical analysis of the CD8b+/CD8b ratio in the
TNF-a-producing and non-producing T-cell population. Here, a sig-
nificant increase in cytotoxic CD8b+ T cells within the TNF-a+ T-cell
population was demonstrated for all the groups (Fig. 5D–F).
Together, these results show a specific increase in CTLs within
TNF-a+ T-cell population independent of the CAF09-formulated
antigen dose.
Moreover, perforin has been reported to be an important effec-
tor molecule for CTLs [18]. Therefore, we also investigated the
effect of antigen dose on the ability of CTLs to produce perforin
in response to TT. A substantial population of perforin+CD8b+ T
cells was detected in all animals (Supp. Fig. 2A). Despite this, no
difference was observed when comparing the percentage of per-
forin+CD8b+ T cells across the groups (Supp. Fig. 2B); hence show-
ing that the production of perforin is independent of the antigen
dose when administered in CAF09 adjuvant.
3.6. Low antigen dose induces more TT-specific polyfunctional T cells
The ability to induce polyfunctional CD4+ T cells in humans has
been shown to be inversely correlated with antigen dose following
intramuscular (i.m.) immunization [4]. Therefore, we investigated
whether an i.p. administration route had similar effect on the abil-
ity to induce polyfunctional T cells in response to CAF09-
adjuvanted TT. Flow cytometric analysis of re-stimulated PBMCs
harvested at day 41 was performed using a gating strategy as
depicted in Supp. Fig. 1. T cells producing both TNF-a and IFN-c
were detected in both the 1 µg and the 10 µg group; however, this
population of double-cytokine-positive T cells appeared to be
mostly absent in the high dose group (Fig. 6A). When quantifying
the percentage of TNF-a+IFN-c+ T cells across the three groups, a
Fig. 1. Immunization with a low antigen dose preferentially drives a CMI response. Göttingen minipigs were intraperitoneally immunized with either 1 µg, 10 µg, or 100 µg of
tetanus toxoid formulated in the CAF09 adjuvant. Immunizations were administered three times with two weeks in between. All animals were blood sampled prior to each
immunization and two weeks post the last injection. (A) IFN-c ELISpot images at day 0 and 41 from one representative animal in each group in response to tetanus toxoid. (B)
Quantification of IFN-c ELISpot responses against tetanus toxoid from animals receiving 1 µg (black circles), 10 µg (grey circles), or 100 µg (white circles). Open squares
indicate the representative animal shown in (A). Data is presented as spot forming cells (SFCs) per 2  105 PBMCs with indication of the mean. (C) ELISA-based detection of
anti-tetanus IgG in serum samples from animals immunized with 1 µg (black circles), 10 µg (grey circles), or 100 µg (white circles). Data is shown as OD values with indication
of the mean. (D) Comparison of IFN-c SFCs in response to tetanus toxoid across all groups and for each time point. Data is shown as mean ± SEM. (E) Comparison of the anti-
tetanus IgG production across all groups and for each time point. Data is shown as mean ± SEM. Statistical evaluation by paired student’s t-test (B and C) or unpaired student’s
t-test (D and E), (n = 5).
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Fig. 2. Flow cytometry corroborates the inverse relationship between antigen dose and the percentage of IFN-c+ T cells. PBMCs purified at day 41 were stimulated in vitro
with tetanus toxoid and IFN-c production was determined by flow cytometry. Analysis included pre-gating on single, viable CD3+ cells. (A) Flow cytometric plots showing
IFN-c+CD3+ cells in the 1 µg (upper panel), 10 µg (middle panel), and 100 µg group (lower panel). Individual animals in each group are shown and horizontally aligned. (B)
Percentage of IFN-c-producing T cells across all groups with indication of the mean. Numbers indicate the percentage of IFN-c+ T cells as a proportion of total T cells. The
background level of IFN-c-producing T cells in response to media alone were at least 2-fold lower when compared to stimulation with TT or 0.03%, while in average 0.36% of
the T cells produced IFN-c in response to the positive SEB stimulation. Statistical evaluation in (B) by unpaired student’s t-test, (n = 5).
Fig. 3. Tetanus-specific cytotoxic CD8b+ T cells are increased within the IFN-c+ T-cell population. PBMCs were harvested at day 41 stimulated in vitro with tetanus toxoid. By
flow cytometry, CD8b expression was individually determined in both the IFN-c and the IFN-c+ T-cell population. Pie charts from animals immunized with either 1 µg (A),
10 µg (B), or 100 µg (C) tetanus toxoid showing the distribution of CD8b (grey) and CD8b+ T cells (black) in both the IFN-c (upper panel) and the IFN-c+ (lower panel) T-cell
population. Individual animals in each group are shown. The CD8b+/CD8b ratio in both the IFN-c (squares) and the IFN-c+ T-cell subsets (triangles) of animals immunized
with 1 µg (D), 10 µg (E), or 100 µg (F) of tetanus toxoid are shown with indication of the mean. Statistical evaluation in D, E, and F by paired student’s t-test (n = 5).
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inducing more polyfunctional T cells (Fig. 6B). It should be noted
that only the 1 µg group clearly demonstrated a population com-
prising IFN-c+ single-producing T cells (Fig. 6A).
4. Discussion and conclusions
During this study, we showed the induction of a CTL response
when administrating CAF09-formulated TT via the i.p. route in
Göttingen minipigs. A low antigen dose resulted in a predominantCMI response, whereas a high dose favoured TT-specific IgG pro-
duction. Previously, TT has been used as a model antigen in pigs
[19], and a study reported the animals to be antigen naïve prior
to immunization [20]. Our data confirmed this; hence showing that
the anti-TT response was indeed vaccine-induced.
Our observed cell- and antibody-mediated responses are not
surprising, as the anti-TT response has been reported to be a mix-
ture between Th1 and Th2 [21,22]. Humans i.m. immunized
against alum-adjuvanted TT showed a strong CD4+ T-cell response
[23], whereas we demonstrated an increased amount of CTLs
Fig. 4. Lowering the antigen dose tends to trigger a higher percentage of TNF-a+ T cells. PBMCs were purified at day 41 and stimulated in vitrowith tetanus toxoid. Production
of TNF-a was determined by flow cytometry, and pre-gating included selection of single, viable CD3+ cells. (A) Flow cytometric plots showing TNF-a+CD3+ cells in the 1 µg
(upper panel), 10 µg (middle panel), and 100 µg group (lower panel). Individual animals in each group are shown and horizontally aligned. (B) Amount of TNF-a-producing T
cells across all groups with indication of the mean. Numbers indicate percentage of TNF-a+ T cells as a proportion of total T cells. The background level of TNF-a-producing T
cells in response to media alone were at least 2-fold lower when compared to stimulation with TT or 0.06%, while in average 0.98% of the T cells produced TNF-a in response
to the positive SEB stimulation. Statistical evaluation in (B) by unpaired student’s t-test, (n = 5).
Fig. 5. The TNF-a+ T-cell population comprises an increased representation of cytotoxic CD8b+ T cells. PBMCs were purified at day 41 and stimulated in vitro with tetanus
toxoid. Flow cytometry analysis included pre-gating on single, viable CD3+ cells, and the CD8b expression was then individually determined in both the TNF-a and the TNF-
a+ T-cell subset. Pie charts from animals immunized with either 1 µg (A), 10 µg (B), or 100 µg (C) of tetanus toxoid showing the distribution of CD8b (grey) and CD8b+ T cells
(black) in both the TNF-a (upper panel) and the TNF-a+ (lower panel) T-cell population. Individual animals in each group are shown. The CD8b+/CD8b ratio in both the TNF-
a and the TNF-a+ T-cell subset from animals immunized with 1 µg (D), 10 µg (E), or 100 µg (F) of tetanus toxoid are shown with indication of the mean. Statistical evaluation
in D, E, and F by paired student’s t-test (n = 5).
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crepancy likely reflects the differences in adjuvants and delivery
route. It is well known that the immune response generated upon
vaccination differs depending on which TLR is activated [24,25]
and i.p. administration of cationic liposomes like CAF09 is superior
in generating strong CTL responses when compared to subcuta-
neous (s.c.) and i.m. injection in mice [26]. Establishment of a
CTL response against a full protein is dependent on cross-
presentation by dendritic cells (DCs); the process by which extra-cellular antigen is taken up and presented in the context of MHC
class I [27,28]. Specifically for i.p. immunizations in mice, vaccine
self-drainage to lymphoid organs was shown to efficiently provide
antigen to cross-presenting DCs [26]. Upon i.p. immunization in
pigs, self-drainage might also play an important role; thus enabling
DCs to effectively prime naïve CD8+ T cells and induce a strong CTL
response. Hence, the observed inverse relationship between anti-
gen dose and the induction of a polyfunctional CMI response might
be differently affected with the use of a different adjuvant system
Fig. 6. A lower antigen dose increases the percentage of IFN-c+TNF-a+ T cells. PBMCs were purified at day 41 and stimulated in vitrowith tetanus toxoid. Cytokine production
was determined by flow cytometry, and the analysis included pre-gating on single, viable CD3+ cells. (A) Representative flow cytometric plots showing IFN-c+TNF-a+ T cells in
the 1 µg (left), 10 µg (middle), and the 100 µg (right) group. (B) Percentage of IFN-c+TNF-a+ T cells as a proportion of total T cells across all groups. Open squares indicate the
representative animal shown in (A). Statistical evaluation in (B) by unpaired student’s t-test, (n = 5).
N.H. Overgaard et al. / Vaccine 35 (2017) 5629–5636 5635comprising other TLR agonists than poly I:C or the use of other
delivery routes.
The antigen dose has previously been shown to influence the
immune response following immunization [29,30]. In both mice
and humans, immunization with a low dose protein induced high
frequencies of CD4+ T cells producing IL-2, IFN-c, and TNF-a
[3,4]. In contrast, our data showed a specific increase in CTLs
within the cytokine-producing T-cell pool. Notably, the studies
reporting a specific induction of polyfunctional CD4+ T cells were
in response to Mycobacterium tuberculosis-derived antigens [3,4],
and protection against this bacteria is known to be dependent on
a CD4+ T-cell response [31–34]. Overall, these studies and our data
all support an inverse relationship between CAF09-formulated
antigen dose and the induction of polyfunctional T cells.
Moreover, the antigen dose has been reported to influence the
avidity and quality of CTLs [35–37]. In addition, the expression
level of inhibitory receptors like PD-1 and CTLA-4 on CD4+ T cells
was found to be decreased, when mice were immunized with a
low antigen dose [5]; Future studies should evaluate the effect of
antigen dose on both the quality and the activation/memory stage
of the TT-reactive T cells in pigs in order to select the optimal strat-
egy for establishment of a vaccine-induced cytotoxic immune
response. In conclusion, our results showed that it is possible to
induce a CTL response by i.p. delivering a CAF09-formulated pro-
tein in pigs. Moreover, we confirmed the inverse relationship
between the antigen dose and the induction of polyfunctional T
cells previously demonstrated in mice and humans. The T-cell sub-
sets affected might differ depending on the antigen in question;
however, the antigen dose clearly affects the immune response
induced by immunization. Therefore, correctly determining the
first-in-human dose becomes even more important. Due to its sim-
ilarities in both metabolism and immunome with humans, we
believe that pigs can serve as an important animal model for pre-
clinical optimization of vaccine doses.
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